A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.

K, Matsueda; S, Harasawa; M, Hongo; N, Hiwatashi; D, Sasaki

doi:10.1159/000150632

Public

A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.

Shared by NobleBlocks on Jun 10, 2008 • 12:00 AM UTC

Authors:

Matsueda K

Harasawa S

Hongo M

Abstract

<h4>Background</h4>Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. Serotonin type 3 (5-HT3) receptor antagonist alosetron hydrochloride is indicated for women with chronic, severe diarrhea-predominant IBS who have not responded adequately to conventional therapy. However, wheth...

Discussions